CBD Stocks on the Rise
May 28, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com --
The marijuana industry has existed in the shadows for decades,
generating tens of billions of dollars a year worldwide. But
with the legalization of recreational marijuana in Canada, and the
expected green light of adult-use weed from Mexico sometime later
this year, cannabis is stepping out of the shadows and into a very
profitable (and legitimate) scenario. One of the biggest
opportunities in the market is CBD because it is already legal in
the US.
Looking at opportunities in the CBD market for investors to
start researching, Real Brands (USOTC:
RLBD) jumps out. The company gives you all the
benefit of the growing market without some of the risk producers
face. RLBD is a branding company that is growing its
portfolio of CBD brands by the day. The company has strong
management with a solid background in branding and the beverage
industry; and plans to expand their holdings focusing on at least
three CBD categories: smokables, edibles and topical balms
and lotions. The company recently updated their logo and
brand identity. It is also developing an E-Commerce website
and plans to launch it during the early part of the second quarter
(which if you’re paying attention could be any day now) on their
newly acquired domain name, to support online sales of a variety of
smokable, edible, and topical CBD derived from hemp-based products
for each of their brands.
The company continues to grow, RLBD just announced that we have
signed a Letter of Intent with Integrative Medicine US, of Coral
Springs, Florida, to acquire their proprietary CBD formulas
consisting of Ancient Chinese Medicine and other Ancient Herbal
Remedies that they have paired with the latest scientific
breakthroughs in endocannabinoid systems, nutrients and CBD.
Start your research today.
Today we are highlighting: Real Brands,
Inc. (USOTC:
RLBD), GW Pharmaceuticals plc (NASDAQ:
GWPH), OrganiGram Holdings (OGI), Aphria Inc. (NYSE:
APHA), and Hexo Corp (AMEX:
HEXO).
Real Brands, Inc. (USOTC:
RLBD) (Market Cap: $11.599M; Share Price:
$0.077) is first and foremost a marketing and
branding company, which has been slowly building its portfolio of
trademarked brand names that could each represent on their own
major partnerships and joint ventures going forward.
Jerry Pearring, the CEO of Real Brands commented, “As the demand
for CBD infused products continues to grow, we intend to create
marketing strategies in at least three CBD Categories: smokables,
edibles and topical balms and lotions.”
Products like CBD gums are something which golfers Tiger Woods and
Phil Mickelson are rumored to be chewing. The
non-psychoactive health benefits of CBD are appealing for
golfers.
That’s why RLBD announcing that PGA professional Scott Piercy is
coming aboard as Brand Ambassador is big news. In March ‘19,
he made a further commitment by making a long-term investment into
Real Brands.
The audit on the horizon means this could also be another major
event for investors to pay attention to. Start your research
today.
________
OTHER CANNABIS COS TO RESEARCH INCLUDE:
GW Pharmaceuticals plc (NASDAQ:
GWPH) (Market Cap: $5.64B; Share Price:
$183.62), the world leader in the
development and commercialization of cannabinoid prescription
medicines, recently announced the appointment of Darren Cline as
its new U.S. Chief Commercial Officer. Mr. Cline will lead the
Epidiolex® U.S. commercial organization and is expected
to start on April 22, 2019.
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on
discovering, developing, and commercializing cannabinoid
prescription medicines using botanical extracts derived from the
Cannabis plant. Its lead product is Epidiolex, an oral
medicine for the treatment of refractory childhood epilepsies, as
well as for the treatment of Dravet syndrome, Lennox-Gastaut
syndrome, tuberous sclerosis complex, and infantile spasms.
GW commercialized the world's first plant-derived cannabinoid
prescription drug, Sativex® (nabiximols), which is approved for the
treatment of spasticity due to multiple sclerosis in numerous
countries outside the United States and for which the company is
now planning a U.S. Phase 3 trial. The company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy,
glioblastoma, and schizophrenia.
________
OrganiGram Holdings (OGI) (Market Cap: $1.161B;
Share Price: $7.49), a leading licensed producer of
cannabis, announced that its common shares will commence trading on
the Nasdaq Global Select Market under the symbol "OGI" on Tuesday
May 21, 2019. Organigram's common shares will continue to be
listed and trade on the Toronto Venture Exchange (TSXV), also
under the symbol "OGI".
________
Aphria Inc. (NYSE:
APHA) (Market Cap: $1.852B; Share Price:
$7.35) shares fell after the Canadian cannabis
company reported fiscal third-quarter results.
It posted a C$108.2 million ($81.1 million) loss for its
fiscal third quarter, or 43 cents a share, after a profit of
C$12.9 million, or 8 cents a share, in the same period a year
ago. Revenue climbed to C$73.6 million from C$10.3 million in
the first full quarter of Canadian legal cannabis. But the
company sold less cannabis than a year ago—kilograms sold fell to
2,636.5 from 3,408.9, while the average retail selling price for
medical cannabis increased to C$8.03 per gram from C$7.51,
primarily because of higher oil sales.
In April, it announced that the previously announced take-over
bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to
meet the statutory minimum tender condition and has now expired and
is terminated. As previously announced on April 15, 2019,
the company entered into a definitive agreement with GGB to
accelerate the expiry date of the Offer to April 25, 2019, as well
as to terminate certain arrangements with GA Opportunities Corp.
("GAOC") for consideration of $89.0 million payable on future dates
as set out in the April 15th press release. The Offer is now
expired and terminated and no longer open to any Aphria shareholder
to tender their shares. Accordingly, GGB will not be taking up any
securities that may have been tendered to the Offer. GGB will
promptly return to the securityholder any Aphria shares tendered
and not withdrawn during the period from the commencement of the
Offer up to the expiry time of the Offer.
________
HEXO Corp (AMEX:
HEXO) (Market Cap: $1.429B; Share Price:
$6.76) and Newstrike Brands Ltd. ("Newstrike")
(TSX-V: HIP) had announced in March that they had entered into
a definitive arrangement agreement (the "Arrangement Agreement")
under which HEXO will acquire all of Newstrike’s issued and
outstanding common shares in an all-share transaction valued at
approximately $263 million. The Transaction
gives HEXO the capacity to produce approximately 150,000
kg of high-quality cannabis annually. The Transaction also
provides HEXO access to four cutting-edge production
campuses totaling close to 1.8 million sq. ft. of near-term
cultivation space and diversified growing and production
techniques. This is in addition to HEXO’s 579,000 sq.
ft. facility for a manufacturing and product development center of
excellence in Belleville, Ontario. HEXO Corp has its headquarters
in Gatineau Canada, and it produces and sells most of its cannabis
products in the country.
The Brantford, Ontario-based Newstrike Brands were granted a
cultivation license on 16 December 2016, and the company expects
its harvest to be about 42,000 kg of cannabis. Although the company
has not been around for long compared to HEXO, it has high capacity
for cannabis production. HEXO recently announced that it had
completed the first harvest in its 1 million sq. ft. expansion,
marking an important execution milestone in the company's
continuous growth.
HEXO Corp., through its subsidiary, HEXO Operations Inc.,
produces, markets, and sells cannabis in Canada. The company
offers dried cannabis under the Time of Day and H2 lines; Elixir, a
cannabis oil sublingual mist product line; and Decarb, an activated
fine-milled cannabis powder product. It provides its products
under the HEXO and Hydropothecary brand names. The company
serves medical and adult-use markets. As one of the largest
licensed cannabis companies in Canada, HEXO Corp operates with
1.8 million sq. ft of facilities in Ontario and Quebec and a
foothold in Greece to establish a Eurozone processing, production
and distribution center.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting has agreed to a three-month
term consulting agreement with RLBD dated 8/31/18. The
agreement calls for $100,000 note issued to Regal Consulting, and
2,500,000 restricted 144 shares of RLBD for three months of
service. Regal has elected to convert $73,000 of principal of
the $100,000 note into 2,761,872 Restricted 144 shares of RLBD.
Regal Consulting has agreed to a twelve- month term consulting
agreement with RLBD dated 1/4/2019. The agreement calls for
$10,000 in cash and 500,000 shares per month. All payments were
made directly by Real Brands, Inc. to Regal Consulting, LLC. to
provide investor relations services, of which this article is a
part of. Regal Consulting also paid one thousand dollars cash
to microcapspeculators.com to distribute this article. Regal
Consulting may have a position in the securities mentioned in this
article at the time of publication, and may increase or decrease
its position without notice. This article is based on public
information and the opinions of Regal Consulting. RLBD was given an
opportunity to edit this article. This article contains
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially
from any results predicted herein. Regal Consulting is not
registered with any financial or securities regulatory authority,
and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
SOURCE: microcapspeculators.com
Real Brands (CE) (USOTC:RLBD)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Real Brands (CE) (USOTC:RLBD)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024